Back

JGOG 2008

Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer

Date of Publication:

January 1, 2008

Pubmed Link:
https://www.ncbi.nlm.nih.gov/pubmed/17996926
Hypothesis:

Does chemotherapy improve OSĀ over EBRT in women with intermediate/high risk endometrial cancer?

Control Arm(s):

cyclophosphamide 333mg/m2

doxorubicin 40mg/m2

cisplatin 50 mg/m2

q4wks x3+ cycles

Experimental Arm(s):

Pelvic EBRT 4500-5000cGy

Primary End Point:

OS

Inclusion Criteria:

stage IC-IIIC endometrioid endometrial carcinoma

>50% myometrial invasion

TAH/BSO with no residual tumor

Exclusion Criteria:
Results:

chemo vs RT:

5yr PFS: 82% vs 83% (NS)

5yr OS: 87% vs 85% (NS)

High intermediate risk group, 5yr PFS (84% vs 66%, SS) and 5yr OS (90% vs 74%, SS) improved with CAP

Defined as: (1) stage IC and >70yo or G3, (2) stage II or IIIA (positive cytology) with >50% myometrial invasion

similar rates of adverse events

Conclusions:

Adjuvant chemotherapy improved OS in women with high intermediate risk endometrial cancer.

Reviewer:
Stephanie Cham, OTF